Analysts upgrade Teva due to improved operations, debt reduction, and stronger cash flow.

Bank of America Securities upgraded Teva Pharmaceutical to Buy and raised its price target, citing improved operations, debt reduction, and progress in restructuring. JPMorgan and UBS also raised their targets, noting stronger cash flow, asset divestitures, and potential in specialty generics and biosimilars. While pricing pressures and legal risks persist, analysts see growing confidence in Teva’s long-term recovery and value creation amid a shift toward operational efficiency and pipeline strength in the pharmaceutical sector.